After keeping a low profile for a few months, Shire is back in the deal meal, again as the predator. Following the announcement to acquire ophthalmology player Foresight Biotherapeutics for $300m on 4 August, it has launched a c.$30bn hostile take-over bid on the US-based Baxalta after being rebuffed in private talks. Apparently, Shire had approached Baxalta in early July and the offer was rejected by Baxalta's management on 31 July.
